| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2017-09-09 08:42:52 UTC |
|---|
| Update Date | 2022-11-30 19:26:41 UTC |
|---|
| HMDB ID | HMDB0116609 |
|---|
| Secondary Accession Numbers | None |
|---|
| Metabolite Identification |
|---|
| Common Name | PG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)) |
|---|
| Description | PG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)) is a phosphatidylglycerol - a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)), in particular, consists of one chain of arachidonic acid at the C-1 position and one chain of cis-vaccenic acid at the C-2 position. Phosphatidylglycerol is present at a level of 1-2% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant (up to 11% of the total). It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for cardiolipin synthesis. |
|---|
| Structure | [H][C@](O)(CO)COP(O)(=O)OC[C@@]([H])(COC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC)OC(=O)CCCCCCCCC\C=C/CCCCCC InChI=1S/C44H77O10P/c1-3-5-7-9-11-13-15-17-19-20-22-23-25-27-29-31-33-35-43(47)51-39-42(40-53-55(49,50)52-38-41(46)37-45)54-44(48)36-34-32-30-28-26-24-21-18-16-14-12-10-8-6-4-2/h11,13-14,16-17,19,22-23,27,29,41-42,45-46H,3-10,12,15,18,20-21,24-26,28,30-40H2,1-2H3,(H,49,50)/b13-11-,16-14-,19-17-,23-22-,29-27-/t41-,42+/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| 1-Arachidonoyl-2-cis-vaccenoyl-sn-glycero-3-phospho-(1'-glycerol) | HMDB | | 1-Arachidonoyl-2-cis-vaccenoyl-sn-glycero-3-phosphoglycerol | HMDB | | PG(20:4/18:1) | HMDB | | PG(20:4N6/18:1N7) | HMDB | | PG(20:4W6/18:1W7) | HMDB | | PG(38:5) | HMDB | | Phosphatidylglycerol(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)) | HMDB | | Phosphatidylglycerol(20:4/18:1) | HMDB | | Phosphatidylglycerol(20:4n6/18:1n7) | HMDB | | Phosphatidylglycerol(20:4W6/18:1W7) | HMDB | | Phosphatidylglycerol(38:5) | HMDB | | GPG(38:5) | HMDB | | GPG(20:4/18:1) | HMDB | | 1-(5Z,8Z,11Z,14Z-Eicosatetraenoyl)-2-(11Z-octadecenoyl)-sn-glycero-3-phospho-(1'-glycerol) | HMDB | | 1-Arachidonoyl-2-vaccenoyl-sn-glycero-3-phosphoglycerol | HMDB | | 1-(5Z,8Z,11Z,14Z-Eicosatetraenoyl)-2-(11Z-octadecenoyl)-sn-glycero-3-phosphoglycerol | HMDB | | [(2S)-2,3-Dihydroxypropoxy][(2R)-3-[(5Z,8Z)-icosa-5,8,11,14-tetraenoyloxy]-2-[(11Z)-octadec-11-enoyloxy]propoxy]phosphinate | HMDB | | 1-arachidonoyl-2-cis-vaccenoyl-sn-glycero-3-phospho-(1'-glycerol) | SMPDB, HMDB | | 1-arachidonoyl-2-cis-vaccenoyl-sn-glycero-3-phosphoglycerol | SMPDB, HMDB | | PG(20:4/18:1) | SMPDB, HMDB | | PG(20:4n6/18:1n7) | SMPDB, HMDB | | PG(20:4w6/18:1w7) | SMPDB, HMDB | | PG(38:5) | SMPDB, HMDB | | Phosphatidylglycerol(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)) | SMPDB, HMDB | | Phosphatidylglycerol(20:4/18:1) | SMPDB, HMDB | | Phosphatidylglycerol(20:4n6/18:1n7) | SMPDB, HMDB | | Phosphatidylglycerol(20:4w6/18:1w7) | SMPDB, HMDB | | PG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)) | SMPDB |
|
|---|
| Chemical Formula | C44H77O10P |
|---|
| Average Molecular Weight | 797.064 |
|---|
| Monoisotopic Molecular Weight | 796.525435677 |
|---|
| IUPAC Name | [(2S)-2,3-dihydroxypropoxy][(2R)-3-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyloxy]-2-[(11Z)-octadec-11-enoyloxy]propoxy]phosphinic acid |
|---|
| Traditional Name | (2S)-2,3-dihydroxypropoxy((2R)-3-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyloxy]-2-[(11Z)-octadec-11-enoyloxy]propoxy)phosphinic acid |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | [H][C@](O)(CO)COP(O)(=O)OC[C@@]([H])(COC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC)OC(=O)CCCCCCCCC\C=C/CCCCCC |
|---|
| InChI Identifier | InChI=1S/C44H77O10P/c1-3-5-7-9-11-13-15-17-19-20-22-23-25-27-29-31-33-35-43(47)51-39-42(40-53-55(49,50)52-38-41(46)37-45)54-44(48)36-34-32-30-28-26-24-21-18-16-14-12-10-8-6-4-2/h11,13-14,16-17,19,22-23,27,29,41-42,45-46H,3-10,12,15,18,20-21,24-26,28,30-40H2,1-2H3,(H,49,50)/b13-11-,16-14-,19-17-,23-22-,29-27-/t41-,42+/m0/s1 |
|---|
| InChI Key | DZLWPARQJZHING-CLJUVTSNSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as phosphatidylglycerols. These are glycerophosphoglycerols in which two fatty acids are bonded to the 1-glycerol moiety through ester linkages. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 positions. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Glycerophospholipids |
|---|
| Sub Class | Glycerophosphoglycerols |
|---|
| Direct Parent | Phosphatidylglycerols |
|---|
| Alternative Parents | |
|---|
| Substituents | - 1,2-diacylglycerophosphoglycerol
- Fatty acid ester
- Dialkyl phosphate
- Dicarboxylic acid or derivatives
- Organic phosphoric acid derivative
- Phosphoric acid ester
- Alkyl phosphate
- Fatty acyl
- 1,2-diol
- Carboxylic acid ester
- Secondary alcohol
- Carboxylic acid derivative
- Organic oxide
- Organooxygen compound
- Alcohol
- Organic oxygen compound
- Primary alcohol
- Carbonyl group
- Hydrocarbon derivative
- Aliphatic acyclic compound
|
|---|
| Molecular Framework | Aliphatic acyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Naturally occurring processBiological processBiochemical pathwayMetabolic pathway- Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)) (PathBank: SMP0072057)
- Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0072058)
- Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z)) (PathBank: SMP0072059)
- Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0072064)
- Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)) (PathBank: SMP0072065)
- Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z)) (PathBank: SMP0072070)
- Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/18:1(9Z)) (PathBank: SMP0079835)
- Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) (PathBank: SMP0079840)
- Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:1(11Z)) (PathBank: SMP0079841)
- Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0079848)
- Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z)) (PathBank: SMP0079850)
- Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z)) (PathBank: SMP0079852)
- Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/18:1(9Z)) (PathBank: SMP0095115)
- Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)) (PathBank: SMP0095118)
- Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:1(11Z)) (PathBank: SMP0095119)
- Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)) (PathBank: SMP0072060)
- Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:1(9Z)) (PathBank: SMP0072068)
- Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) (PathBank: SMP0072075)
- Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/20:4(5Z,8Z,11Z,14Z)/18:1(11Z)) (PathBank: SMP0079834)
- Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0079853)
- Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(11Z)) (PathBank: SMP0072072)
|
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. | 6.75 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 33.4768 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.94 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 5780.5 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 336.5 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 333.6 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 239.6 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 1209.8 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 1901.6 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 1110.9 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 232.1 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 3480.1 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 1248.8 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 2989.2 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 1359.5 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 763.9 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 310.0 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 672.3 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 11.1 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatized |
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - PG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)) GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-13 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - PG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)) GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-10-19 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - PG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)) GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-10-19 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - PG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)) GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-10-19 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - PG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)) 10V, Positive-QTOF | splash10-00or-3091231600-e2e04ec1340a7e68b20c | 2019-02-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - PG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)) 20V, Positive-QTOF | splash10-05r0-4191111300-29104da0d9113a631472 | 2019-02-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - PG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)) 40V, Positive-QTOF | splash10-0a4j-7095102200-4f07f41996c164085d29 | 2019-02-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - PG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)) 10V, Negative-QTOF | splash10-0uei-1195030500-0a5b8acfbfd945b7ad9d | 2019-02-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - PG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)) 20V, Negative-QTOF | splash10-0ufr-9488210200-f1b18393883b55bd314b | 2019-02-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - PG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)) 40V, Negative-QTOF | splash10-004i-9011000000-c49767f5c84c10aecde0 | 2019-02-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - PG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)) 10V, Negative-QTOF | splash10-0002-0000000900-9869f21529424c0a4adf | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - PG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)) 20V, Negative-QTOF | splash10-0uf1-0199440900-fb9570ac29ea5d70c8a4 | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - PG(20:4(5Z,8Z,11Z,14Z)/18:1(11Z)) 40V, Negative-QTOF | splash10-0uea-0399440900-f7723e9195605225a4ac | 2021-09-24 | Wishart Lab | View Spectrum |
|
|---|
| Pathways | |
|---|